AKT1 and acute myeloid leukemia: Interestingly, our observation of mTOR and PI3K downregulation contrasts with reports of mTOR/AKT/PI3K hyperactivation in AML, reflecting the heterogeneity of AML subtypes and patient‐specific molecular profiles.